0001213900-26-055058
SEC filingA transitional quarter with revenue declining sharply as legacy licensing income ended, while the company invested in R&D for VT-1953, funded by recent merger and ATM proceeds.
Revenue for the three months ended March 31, 2026, was $31.6K, a decrease of 97% from $1.1M in the same period last year. This decline was primarily due to the termination of the Sun Pharma licensing agreement in 2024, which had been the primary source of revenue. The company is now focused on advancing its own pipeline, particularly VT-1953.
Research and development expenses increased as the company allocated resources to regulatory consulting and CMC preparation work for the VT-1953 project. This investment reflects the company's strategic shift toward developing its own drug candidates.
Net income swung to a loss of $962.9K from a gain of $1.5M in the prior year. The prior year's gain was primarily due to fair value gains on derivative liabilities, which did not recur in the current period. Diluted EPS was ($0.15) compared to $18.98 in the prior year.
The company continues to operate under cost-efficient operations for capital efficiency. Future liquidity needs may be met through additional financing, including potential contracts with clinical research organizations and vendors. The company's ability to continue as a going concern depends on its ability to raise capital and successfully develop its pipeline.